The vast majority of biotech stocks joined a broad market decline on Monday as losers exceeded gainers with Repros Therapeutics Inc (NASDAQ:RPRX) losing the most after change of plans to announce data from a clinical trial of its Androxal treatment for secondary hypogonadism during the third quarter instead of the second quarter.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) declined 4.63% before its management meets Brean Capital in Boston on January 30. [article_detail_ad_1]
Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), Novavax, Inc. (NASDAQ:NVAX), Hemispherx BioPharma, Inc (NYSEAMEX:HEB) and Rexahn Pharmaceuticals, Inc. (NYSEAMEX:RNN) each fell more than 3% while Charles River Laboratories (NYSE:CRL) and Sarepta Therapeutics Inc (NASDAQ:SRPT) each dropped about 2%.
ImmunoGen, Inc. (NASDAQ:IMGN) extended fall after results.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continued to decline before its earnings release late Tuesday.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) lost 1.72% after TheStreet Ratings recommended selling the stock with a ratings score of D-.
CEL-SCI Corporation (NYSEAMEX:CVM), InterMune, Inc. (NASDAQ:ITMN), Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), Medivation, Inc. (NASDAQ:MDVN) and Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR)
Theravance Inc (NASDAQ:THRX) traded 0.85% down after Piper Jaffray analysts reduced their price objective on the stock to $32.00.
Illumina, Inc. (NASDAQ:ILMN) traded lower before its financial results for the fourth quarter and fiscal year of 2012. Genetic analysis Instrument Company has posted a sharp growth in profit for the fourth quarter, due mainly to higher revenues.
Celgene Corporation (NASDAQ:CELG) turned red on Monday after Argus downgraded the stock from a “buy” rating to a “hold” rating.
Despite hitting new highs, Gilead Sciences, Inc. (NASDAQ:GILD) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) both finished the day in red.
Peregrine Pharmaceuticals (NASDAQ:PPHM) retreated 0.48% yesterday after a Motley Fool article.
More on the flip side, Nektar Therapeutics (NASDAQ:NKTR), Exelixis, Inc. (NASDAQ:EXEL), Dyax Corp. (NASDAQ:DYAX), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and VIVUS, Inc. (NASDAQ:VVUS) all lost between 0 and 0.5 percent.
Surprisingly, Corcept Therapeutics Incorporated (NASDAQ:CORT), Cell Therapeutics Inc (NASDAQ:CTIC) and MannKind Corporation (NASDAQ:MNKD) showed no change by the end of trade on Monday.
On the upside, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) rose 8.16% to become one of the biggest gainers in the biotechnology industry.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), Celsion Corporation (NASDAQ:CLSN) and Sequenom, Inc. (NASDAQ:SQNM) each rose more than 5% while Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) advanced 3.83%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) marked new high after Cowen commenced coverage on the stock with an outperform rating.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) trimmed early gains, ending the day up 3.81% after signing a non-exclusive partnership deal with Janssen Pharmaceuticals, Inc. for the clinical development of all-oral direct-acting antiviral (DAA) HCV combination therapies.
Amgen, Inc. (NASDAQ:AMGN) extended rally after results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Biogen Idec Inc. (NASDAQ:BIIB) added 2.59% after quarterly results.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) scored new high after Piper Jaffray analysts maintained their Overweight rating on the stock.
Dendreon Corporation (NASDAQ:DNDN) and DARA Biosciences Inc (NASDAQ:DARA) increased at-least 1% while Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Galena Biopharma Inc (NASDAQ:GALE), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Incyte Corporation (NASDAQ:INCY) all rose in a range of 0 to 1%.